• 목록
• 게시판 리스트 옵션
  • 수정
  • 삭제

ADHD Medication During Pregnancy and Breastfeeding

Women with ADHD face a difficult decision about whether to continue or stop taking ADHD medication during pregnancy and breast-feeding. Little data exists about how long-term exposure to these drugs may affect the foetus.

A study recently published in Molecular Psychiatry shows that children exposed to ADHD medication during the uterus do not develop neurological developmental disorders like impaired vision or hearing seizures, febrile seizures or IQ impairment. The authors acknowledge that further high-quality studies are needed.

Risk/Benefit Analysis

Women who are pregnant and take ADHD medication need to consider the benefits of taking it against the potential risks for the foetus. Doctors don't have enough data to provide clear recommendations however they can provide information on the risks and benefits to assist pregnant women to make informed choices.

A study published in Molecular Psychiatry found that women who used ADHD medications during early pregnancy did not face an higher risk of fetal cardiac malformations or major birth defects that are structural. Researchers conducted a large population-based study of case-control to evaluate the incidence of major structural birth defects in infants born to mothers who had taken stimulants during the early stages of pregnancy and those who had not. Pediatric cardiologists, clinical geneticists and other experts reviewed the cases in order to confirm that the classification was accurate and to reduce any bias.

The research conducted by the researchers had some limitations. Most important, they were unable to separate the effects of the medication from the effects of the underlying disorder. This limitation makes it difficult to know whether the limited associations observed in the groups that were exposed result from medication use or comorbidities that cause confusion. The researchers also did not look at long-term outcomes best medicine for adhd and social anxiety the offspring.

The study showed that infants whose mother took ADHD medication during pregnancy had a higher chance of being admitted to the neonatal care unit (NICU) in comparison to those whose mothers did not use any medication during pregnancy or had stopped taking their medication before or during pregnancy. This was due to central nervous system-related disorders and the increased risk for admission did not appear to be affected by the type of stimulant medications were taken during pregnancy.

Women who took stimulant ADHD medication during pregnancy also had an elevated risk of having a caesarean birth or having a child with an low Apgar score (less than 7). These increases appear to be unrelated to the type of medication used during pregnancy.

Researchers suggest that the small risks posed by the use of ADHD medication during pregnancies in the early stages may be offset by the greater benefits to both mother and baby from continuing treatment for the woman’s disorder. Physicians should discuss this with their patients and, if possible, help them develop strategies for improving their coping skills that may minimize the negative impact of her condition on her daily life and relationships.

Medication Interactions

Many doctors are faced with the decision of whether to continue treatment or stop during pregnancy as more women are diagnosed with ADHD. These decisions are often made without clear and authoritative evidence. Instead, physicians must take into account their own experience and experience, as well as the experiences of other doctors and the research on the subject.

Particularly, the issue of potential risks to the infant can be difficult. Many of the studies on this subject are based on observational data rather than controlled research, and their findings are often contradictory. Most studies restrict their analysis to live-births, which could underestimate the teratogenic impact which can cause terminations or abortions of pregnancy. The study discussed in this journal club addresses these limitations by examining data on both live and deceased births.

The conclusion: While some studies have shown an association between ADHD medications and the possibility of certain birth defects, others have found no connection, and most studies have a neutral or slight negative effect. In all cases it is imperative to conduct a thorough evaluation of the potential risks and benefits should be conducted.

For women suffering from ADHD and ADD, the decision to stop medication is difficult, if not impossible. In fact, in an article published in the Archives of Women's Mental Health psychologist Jennifer Russell notes that stopping ADHD medication during pregnancy can increase depression, feelings of isolation, and family conflict for these patients. A decrease in medication could affect the ability to safely drive and perform work-related tasks, which are vital aspects of everyday life for people with ADHD.

She suggests that women who aren't sure whether to continue taking the medication or discontinue it due to pregnancy should educate family members, coworkers, and acquaintances about the condition, its impact on daily functioning and the benefits of continuing the current treatment regimen. It can also help a woman feel supported in her decision. It is important to note that certain medications can be absorbed through the placenta so if the patient decides to discontinue her ADHD medication during pregnancy and breastfeeding, she must be aware that the effects of the drug can be passed on to the baby.

Risk of Birth Defects

As the use of ADHD medications to treat symptoms of attention deficit hyperactivity disorder (ADHD) grows as do concerns about what adhd medications are there uk impact the drugs might have on the fetuses. A study that was published in the journal Molecular Psychiatry adds to the body of knowledge on this subject. Researchers utilized two massive data sets to examine more than 4.3 million pregnancy and determine if the use of stimulant medications increased the risk of birth defects. Researchers discovered that although the overall risk is low, first-trimester ADHD medication exposure was associated with slightly higher rates of certain heart defects, such as ventriculoseptal defect.

The authors of the study found no link between early use of medication and congenital abnormalities like facial clefting, or club foot. The results are consistent with previous studies that have shown a small but significant increase in the risk of cardiac malformations among women who began taking ADHD medications prior to the time of pregnancy. The risk grew in the later part of pregnancy, when many women decide to stop taking their ADHD medication.

Women who took adhd medication pregnancy (relevant site) medication in the first trimester were more likely to require a caesarean delivery or have a low Apgar after birth and have a baby that needed help breathing at birth. The researchers of the study were unable to eliminate bias due to selection because they restricted the study to women who did not have any other medical conditions that could have contributed to the findings.

The researchers hope their research will aid in the clinical decisions of physicians who see pregnant women. The researchers recommend that while discussing risks and benefits are important, the choice regarding whether or not to stop medication should be according to the severity of each woman's ADHD symptoms and the needs of the woman.

The authors caution that, while stopping the medication is an option to consider, it is not recommended due to the high rate depression and other mental disorders among women who are pregnant or who have recently given birth. Research has also shown that women who stop taking their medication will have a tough adjustment to life without them after the baby is born.

Nursing

It can be overwhelming becoming a mother. Women who suffer from ADHD who have to deal with their symptoms while attending physician appointments, getting ready for the arrival of their child and adjusting to new household routines can experience severe challenges. Many women opt to continue taking their ADHD medication during pregnancy.

The majority of stimulant medications are absorbed by breast milk in very small amounts, so the risk to the nursing infant is very low. The rate of medication exposure will differ based on dosage, frequency of administration and time of day. In addition, individual medications enter the body of the baby differently through the gastrointestinal tract as well as breast milk, and the effect of this on a newborn isn't yet fully known.

Some doctors may decide to stop stimulant medications during a woman's pregnancy due to the absence of research. This is a difficult decision for the patient, who must weigh the benefit of continuing her medication against the possible dangers to the embryo. In the meantime, until more information is available, doctors can ask pregnant patients whether they have an background of ADHD or if they plan to take medication during the perinatal phase.

A growing number of studies have revealed that most women can safely continue taking their ADHD medication during pregnancy and while breastfeeding. In the end, many patients opt to do this and in consultation with their physician, they have found that the benefits of keeping their current medication far exceed any risk.

Women who suffer from ADHD who are planning to breastfeed should seek the advice of a specialist psychiatrist before becoming pregnant. They should discuss their medication with their doctor and discuss the advantages and disadvantages of continuing treatment, including non-pharmacological management strategies. Psychoeducation is also needed to help pregnant women with ADHD understand the symptoms and underlying disorder. They should also be informed about treatment options and build strategies for coping. This should be an approach that is multidisciplinary, including the GP as well as obstetricians, psychiatry and obstetricians. Pregnancy counseling should include discussion of a treatment plan for the mother and the child, and monitoring for signs of deterioration and, if necessary adjustments to the medication regime.